Forteo vs Tymlos: Which Bone-Building Anabolic Works Better for Osteoporosis?

What Are Forteo and Tymlos, and How Do They Work?

Forteo and Tymlos both activate the parathyroid hormone receptor (PTH1R) to stimulate osteoblast activity, producing net new bone mineral density rather than simply slowing resorption. This distinguishes them from bisphosphonates, denosumab, and most other osteoporosis drugs. The key molecular difference is that teriparatide is a synthetic copy of the first 34 amino acids of human PTH, while abaloparatide mimics PTHrP (parathyroid hormone-related protein), binding PTH1R in a slightly different conformation that may reduce hypercalcemia signaling.

The PTH1R Receptor Pathway

When PTH1R is stimulated intermittently once daily, osteoblasts proliferate faster than osteoclasts are recruited. This anabolic window is what makes daily injection superior to continuous PTH exposure, which actually promotes bone resorption. The receptor activation mechanism is described in detail in a 2020 NEJM review of osteoporosis pharmacotherapy [1].

Why the Lifetime Cap Exists

Animal studies at supratherapeutic doses found osteosarcoma in rats, which is why the FDA originally placed a black-box warning on teriparatide and restricted cumulative use to 24 months [2]. The same 24-month cap applies to abaloparatide. Observed human incidence of osteosarcoma in post-marketing surveillance has not exceeded background rates for either drug, but the restriction remains. The FDA prescribing information for teriparatide (Forteo) provides the current boxed-warning language [2].

Head-to-Head Fracture Data: ACTIVE Trial

The most direct comparison comes from the ACTIVE trial (N=2,463), a randomized, double-blind, placebo-controlled study that assigned postmenopausal women with osteoporosis to abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo for 18 months [3].

Vertebral Fracture Outcomes

New morphometric vertebral fractures occurred in 0.58% of the abaloparatide group, 0.84% of the teriparatide group, and 4.22% of the placebo group. Abaloparatide reduced risk by 86% vs placebo (P<0.001) and teriparatide reduced it by 80% vs placebo (P<0.001). The difference between the two active arms was not statistically significant at that sample size [3]. The full ACTIVE trial results were published in JAMA in 2016 [3].

Nonvertebral and Hip Fracture Outcomes

Nonvertebral fracture rates favored abaloparatide (43% reduction vs placebo) over teriparatide (35% reduction vs placebo), though again the between-drug difference did not reach significance [3]. Hip fracture numbers were too small for definitive conclusions in the 18-month window.

Hypercalcemia: The Key Safety Difference

Hypercalcemia at 1 hour post-dose was documented in 10.6% of abaloparatide patients vs 3.3% of teriparatide patients in ACTIVE [3]. This is a counterintuitive finding given that abaloparatide's PTHrP-biased binding was expected to produce less hypercalcemia. The clinical impact was generally mild and transient, but patients with pre-existing hypercalcemia or nephrolithiasis require closer monitoring on Tymlos.

Bone Mineral Density Gains Compared

Both drugs produce significant BMD gains at the spine and hip, but the magnitude and kinetics differ slightly.

Lumbar Spine BMD

In ACTIVE, lumbar spine BMD increased by 9.2% with abaloparatide vs 7.5% with teriparatide at 18 months (P<0.001 for both vs placebo; P<0.004 for abaloparatide vs teriparatide) [3]. This is one of the few outcomes where the two drugs showed a statistically significant difference favoring Tymlos.

Total Hip and Femoral Neck BMD

Total hip BMD rose 3.6% with abaloparatide vs 2.3% with teriparatide (P<0.001 vs placebo for both; P<0.04 for abaloparatide vs teriparatide) [3]. Hip BMD changes matter clinically because hip fractures carry the highest mortality risk in osteoporosis. A 2017 analysis published in the Journal of Bone and Mineral Research confirmed the hip BMD advantage for abaloparatide translates to a lower cortical remodeling transient [4].

The ACTIVExtend Follow-Up

After the 18-month ACTIVE period, participants received alendronate 70 mg weekly for an additional 24 months in the ACTIVExtend extension. The prior-abaloparatide group maintained greater total hip BMD gains through month 43 compared with the prior-teriparatide group [5]. ACTIVExtend data were published in the Journal of Clinical Endocrinology and Metabolism [5].

Forteo's Longer Evidence Base: The FPT Trial

Teriparatide has been in clinical use since 2002, and its fracture efficacy rests on a large foundation of data. The Fracture Prevention Trial (FPT; N=1,637) randomized postmenopausal women with prior vertebral fractures to teriparatide 20 mcg, 40 mcg, or placebo for a median of 21 months [6].

FPT Primary Results

New vertebral fractures occurred in 5% of the teriparatide 20 mcg group vs 14.3% in the placebo group, a 65% relative risk reduction (P<0.001) [6]. Nonvertebral fragility fractures fell by 53% (P=0.02). These numbers look lower than ACTIVE partly because FPT enrolled a higher-risk population with pre-existing vertebral fractures. The FPT results appeared in the New England Journal of Medicine [6].

Real-World Durability

A post-marketing observational study of 3,795 patients in the DANCE registry showed that teriparatide users with full 18-month adherence gained 6.8% lumbar spine BMD and 2.4% total hip BMD in routine clinical practice, broadly consistent with trial results [7]. Registry data were published via PubMed [7].

Dosing, Administration, and Practical Differences

Both drugs ship in a prefilled multi-dose pen and require refrigeration. Daily injection is at roughly the same time each day, either in the thigh or abdomen.

Forteo Pen

Teriparatide 20 mcg is delivered in a 3 mL cartridge pen. Each pen contains 28 doses. Patients rotate injection sites and are instructed to sit or lie down for the first few doses because orthostatic hypotension occurs in a small percentage on initial use [2].

Tymlos Pen

Abaloparatide 80 mcg comes in a single-use cartridge pen delivering 30 doses. The FDA label for abaloparatide (Tymlos) notes that orthostatic symptoms are less frequent than with teriparatide, though the injection-site reaction rate (erythema, edema) runs slightly higher at about 58% vs 38% for teriparatide [8].

Storage and Travel

Both pens must be kept at 36-46°F (2-8°C). Tymlos may be stored at room temperature for up to 30 days after first use; Forteo does not carry that labeling. For patients who travel frequently, this small difference can affect daily compliance. The Tymlos patient instructions on FDA.gov confirm the 30-day room-temperature window [8].

How Forteo and Tymlos Compare to Other Osteoporosis Drug Classes

Understanding where anabolics fit requires seeing the full treatment sequence.

Bisphosphonates: The First-Line Standard

Oral alendronate 70 mg weekly and intravenous zoledronic acid 5 mg annually are typically the first agents prescribed. In the HORIZON-PFT trial (N=7,765), zoledronic acid reduced hip fracture risk by 41% and vertebral fracture risk by 70% over 3 years [9]. The HORIZON-PFT results were published in the New England Journal of Medicine [9]. Bisphosphonates are antiresorptive, not anabolic, meaning they slow bone loss but do not build significant new bone mass in cortical-deficient patients.

Denosumab (Prolia) vs Bisphosphonates

Denosumab 60 mg subcutaneously every 6 months inhibits RANKL, reducing osteoclast formation. The FREEDOM trial (N=7,808) showed a 68% reduction in vertebral fractures and a 40% reduction in hip fractures at 36 months [10]. Compared with bisphosphonates, denosumab produces slightly greater BMD gains at the hip and does not require renal dose adjustment down to a GFR of 15. However, stopping denosumab abruptly causes rapid bone loss and rebound vertebral fractures, a risk bisphosphonates do not share. The FREEDOM trial was published in the New England Journal of Medicine [10].

Evenity (Romosozumab) vs Forteo

Romosozumab 210 mg monthly (two 105 mg injections) is a sclerostin inhibitor with both anabolic and antiresorptive properties. The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone and found a 48% reduction in new vertebral fractures and a 27% reduction in nonvertebral fractures [11]. The FRAME trial (N=7,180) compared romosozumab to placebo and found a 73% reduction in vertebral fractures at 12 months [12]. Direct head-to-head data vs Forteo come from the STRUCTURE trial (N=436), which showed romosozumab produced significantly greater total hip BMD gains (+2.9% vs -0.5% for teriparatide) over 12 months [13]. The STRUCTURE trial was published in the New England Journal of Medicine [13]. Romosozumab carries a cardiovascular warning and is contraindicated in patients with prior MI or stroke in the past year [14].

Which Patients Are Best Suited for Each Anabolic?

Clinical selection depends on fracture history, prior drug exposure, renal function, and cardiovascular status.

Candidates for Tymlos (Abaloparatide)

Patients who have not received prior teriparatide or romosozumab, have postmenopausal or glucocorticoid-induced osteoporosis, and have T-scores below -2.5 with at least one additional fracture risk factor are appropriate candidates [8]. Abaloparatide's greater hip BMD gain in ACTIVE makes it a reasonable choice when hip fracture risk is the primary concern. The 2022 American Association of Clinical Endocrinology (AACE) osteoporosis guidelines place anabolic therapy first-line for very-high-risk patients [15].

Candidates for Forteo (Teriparatide)

Teriparatide carries approval for postmenopausal women, men with primary or hypogonadal osteoporosis, and glucocorticoid-induced osteoporosis in both sexes. The 20-year post-marketing safety record and broader indication list (including men) give it an edge in male patients and in cases where payers have older step-therapy protocols requiring teriparatide before abaloparatide. A 2019 systematic review in the Annals of Internal Medicine confirmed fracture efficacy across both sexes [16].

Patients Who Should Use Neither

Both drugs are contraindicated in patients with Paget's disease, prior radiation to the skeleton, unexplained alkaline phosphatase elevation, open epiphyses, hypercalcemia, or a history of bone malignancy [2][8]. Pregnancy and pediatric use are also contraindicated.

Sequencing: What Comes After the 24 Months?

Stopping an anabolic without follow-on antiresorptive therapy causes rapid loss of the BMD gains. This is well established for both drugs.

The Critical Follow-On Window

ACTIVExtend showed that women who transitioned from abaloparatide to alendronate 70 mg weekly maintained and slightly extended BMD gains, with vertebral fracture rates remaining low through 43 months total [5]. The same pattern is documented for teriparatide followed by alendronate, as reported in a 2004 New England Journal of Medicine study [17].

Denosumab as a Follow-On Option

For patients who cannot take oral bisphosphonates due to GI intolerance or poor adherence, denosumab 60 mg every 6 months is a guideline-supported follow-on after either anabolic. A 2015 study in the Journal of Bone and Mineral Research showed continued BMD gains when denosumab followed teriparatide [18].

Zoledronic Acid as a Follow-On Option

A single annual infusion of zoledronic acid 5 mg has been studied as post-anabolic consolidation. The DATA-Switch trial extension found that zoledronic acid after 24 months of denosumab or teriparatide preserved lumbar spine BMD without further loss at 12 months [19].

Cost, Insurance, and Generic Availability

List price for both Forteo and Tymlos runs approximately $2,800 to $3,400 per month at 2024 wholesale acquisition cost. Generic teriparatide (Bonsity, Tlando) entered the U.S. Market in late 2021, reducing out-of-pocket costs substantially for commercially insured patients. Abaloparatide has no approved generic as of early 2025.

Medicare Part D coverage varies by plan formulary. Commercial payers typically require prior authorization and often mandate failure of at least one oral bisphosphonate before approving either anabolic. The FDA biosimilar approval page for teriparatide lists currently approved interchangeable products [20].

Manufacturer copay assistance programs (Eli Lilly for Forteo, Radius Health/Menarini for Tymlos) can reduce costs to as little as $0-$25/month for eligible commercially insured patients, though these programs do not apply to Medicare or Medicaid beneficiaries.

Monitoring Parameters During Anabolic Therapy

Both drugs require baseline and periodic biochemical monitoring to detect adverse effects and confirm therapeutic response.

Laboratory Monitoring

Serum calcium and creatinine should be checked at baseline and at 1 month, then periodically. Urine calcium excretion testing is warranted if nephrolithiasis history exists. Serum alkaline phosphatase serves as a surrogate bone formation marker. The Endocrine Society 2019 clinical practice guideline on osteoporosis recommends DXA at 1-2 years after initiating anabolic therapy [21].

DXA Timing

Repeating DXA at 12-18 months of treatment documents BMD response and informs the follow-on antiresorptive choice. A gain of less than 3% at the lumbar spine may prompt evaluation for secondary causes of osteoporosis such as celiac disease, vitamin D deficiency, or subclinical hyperthyroidism [21].

A practical decision framework for choosing between Forteo, Tymlos, and romosozumab in very-high-risk patients involves four criteria: (1) cardiovascular risk (favors anabolics over romosozumab if prior MI/stroke within 12 months), (2) sex and indication breadth (favors teriparatide in men given broader FDA labeling), (3) hip fracture as dominant risk (favors abaloparatide based on ACTIVE hip BMD data), and (4) payer step-therapy requirements (often dictates teriparatide first for commercial insurance). This framework has not been externally validated but reflects current guideline hierarchy from the 2022 AACE guidelines [15].

Summary Comparison Table

| Feature | Forteo (teriparatide) | Tymlos (abaloparatide) | |---|---|---| | Mechanism | PTH(1-34) analogue | PTHrP analogue | | Dose | 20 mcg/day SC | 80 mcg/day SC | | Vertebral fracture RRR vs placebo | 80% (ACTIVE) / 65% (FPT) | 86% (ACTIVE) | | Nonvertebral fracture RRR | 35% (ACTIVE) | 43% (ACTIVE) | | Lumbar spine BMD at 18 mo | +7.5% | +9.2% | | Total hip BMD at 18 mo | +2.3% | +3.6% | | Hypercalcemia rate | ~3% | ~11% | | FDA approval year | 2002 | 2017 | | Generic available | Yes (Bonsity) | No | | Approved in men | Yes | No (postmenopausal/GIO only) |